disease, and patients with metastatic MM should be thoroughly evaluated for progression of disease.8 Our patient was started on lenalidomide and dexamethasone, and palliative external beam radiation was administered to the cutaneous lesions.
DISCLOSURES
The authors have no conflicts of interest to declare.
REFERENCES
- Patterson JW, Parsons JM, White RM, Fitzpatrick JE, Kohout-Dutz E. Cutaneous involvement of multiple myeloma and extramedullary plasmacytoma. J Am Acad Dermatol. 1988;19:879-890.
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
- Bayer-Garner IB, Smoller BR. The spectrum of cutaneous disease in multiple myeloma. J Am Acad Dermatol. 2003;48(4):497-507.
- Karimkhani C, Smith C. Extraosseous extension of multiple myeloma: a cutaneous herald to systemic disease. J Am Acad Dermatol. 2014;71(3):e73-e74.
- Kubica AW, Wetter DA, Lehman JS. Cutaneous involvement by multiple myeloma. Am J Hematol. 2014;89(10):1014-1015.
- Alberts DS, Lynch P. Cutaneous plasmacytomas in myeloma. Relationship to tumor cell burden. Arch Dermatol. 1978;114(12):1784-1787.
- Ballester-MartÃnez MA1, González-GarcÃa C, Fleta-AsÃn B, et al. Cutaneous nodules as a diagnostic clue in multiple myeloma. Am J Dermatopathol. 2013;35(3):377-380.
- Comfere NI, Gonzalez Santiago TM, Peters MS, Knudson RA, Ketterling RP, Gibson LE. Cutaneous extramedullary plasmacytoma: clinical, prognostic, and interphase cytogenetic analysis. Am J Dermatopathol. 2013;35(3):357-363.
AUTHOR CORRESPONDENCE
Jeffrey Scott MDjeffrey.scott@uhhospitals.org